InspireMD's Q1 2025: Navigating FDA Approval Contradictions and Strategic Hiring Challenges
Earnings DecryptTuesday, May 20, 2025 1:24 am ET

FDA approval timeline and enrollment progress, commercial hiring and growth strategy, C-Guardians 2 IDE study timeline, and FDA approval timeline and enrollment progress are the key contradictions discussed in InspireMD's latest 2025Q1 earnings call.
CGuard Revenue Growth:
- reported CGuard revenue of $1.53 million for Q1 2025, reflecting 1.2% year-over-year growth.
- The growth was driven by an increase in unit sales, with 2,611 CGuard stents sold, reflecting strong patient demand and market adoption.
CGuard Prime Approval and Market Potential:
- Based on communication with the FDA, InspireMD is optimistic about securing approval for CGuard Prime by Q3 2025.
- The introduction of CGuard Prime is expected to significantly expand the U.S. market due to its superior patient outcomes and next-generation performance.
Commercial and Clinical Investments:
- InspireMD has strategically expanded its commercial and clinical foundation by hiring and training 20 high-powered sales and marketing professionals.
- These investments aim to drive robust growth over the coming years, capitalizing on the shift towards endovascular-first solutions in carotid revascularization.
Clinical Trial Progress:
- The enrollment in the C-GUARDIANS II pivotal study of CGuard Prime carotid stent system continues to progress strongly, with 8 active sites and positive feedback from doctors.
- The study is on track to achieve its clinical milestones, with an anticipated FDA approval in the first half of 2026.
M&A and Financial Position:
- InspireMD's total revenue increased by 1.2% to $1,529,000 in Q1 2025, driven by growth in existing markets despite foreign exchange impacts.
- The company has maintained a strong financial position with $26,086,000 in cash and cash equivalents and marketable securities as of March 31, 2025.
CGuard Revenue Growth:
- reported CGuard revenue of $1.53 million for Q1 2025, reflecting 1.2% year-over-year growth.
- The growth was driven by an increase in unit sales, with 2,611 CGuard stents sold, reflecting strong patient demand and market adoption.
CGuard Prime Approval and Market Potential:
- Based on communication with the FDA, InspireMD is optimistic about securing approval for CGuard Prime by Q3 2025.
- The introduction of CGuard Prime is expected to significantly expand the U.S. market due to its superior patient outcomes and next-generation performance.
Commercial and Clinical Investments:
- InspireMD has strategically expanded its commercial and clinical foundation by hiring and training 20 high-powered sales and marketing professionals.
- These investments aim to drive robust growth over the coming years, capitalizing on the shift towards endovascular-first solutions in carotid revascularization.
Clinical Trial Progress:
- The enrollment in the C-GUARDIANS II pivotal study of CGuard Prime carotid stent system continues to progress strongly, with 8 active sites and positive feedback from doctors.
- The study is on track to achieve its clinical milestones, with an anticipated FDA approval in the first half of 2026.
M&A and Financial Position:
- InspireMD's total revenue increased by 1.2% to $1,529,000 in Q1 2025, driven by growth in existing markets despite foreign exchange impacts.
- The company has maintained a strong financial position with $26,086,000 in cash and cash equivalents and marketable securities as of March 31, 2025.

Disclaimer: The news articles available on this platform are generated in whole or in part by artificial intelligence and may not have been reviewed or fact checked by human editors. While we make reasonable efforts to ensure the quality and accuracy of the content, we make no representations or warranties, express or implied, as to the truthfulness, reliability, completeness, or timeliness of any information provided. It is your sole responsibility to independently verify any facts, statements, or claims prior to acting upon them. Ainvest Fintech Inc expressly disclaims all liability for any loss, damage, or harm arising from the use of or reliance on AI-generated content, including but not limited to direct, indirect, incidental, or consequential damages.
Comments
No comments yet